Successful Treatment of Sarcomatoid Carcinoma Using Nivolumab Plus Ipilimumab Combination Immunotherapy: a Case Report

Q4 Medicine

Japanese Journal of Lung Cancer Pub Date : 2022-12-20 DOI:10.2482/haigan.62.996

Hiroki Watanabe, Yuihci Murai, Asumi Suzuki, Ikumi Yamagishi, E. Ogata, T. Miyabayashi, Akira Youkou, Masatoshi Watanabe, T. Abe

{"title":"Successful Treatment of Sarcomatoid Carcinoma Using Nivolumab Plus Ipilimumab Combination Immunotherapy: a Case Report","authors":"Hiroki Watanabe, Yuihci Murai, Asumi Suzuki, Ikumi Yamagishi, E. Ogata, T. Miyabayashi, Akira Youkou, Masatoshi Watanabe, T. Abe","doi":"10.2482/haigan.62.996","DOIUrl":null,"url":null,"abstract":". ABSTRACT ━━ Background. Pulmonary pleomorphic carcinoma, a subtype of sarcomatoid carcinoma, is a rare lung malignancy. This cancer is usually resistant to chemo- and radiotherapy, and no standard treatment proto-cols are currently available. We herein report a case of sarcomatoid carcinoma in a patient who responded to combination therapy using nivolumab plus ipilimumab. Case. A 62-year-old man who was a current smoker was re-ferred to our hospital with right lower extremity paresis. Computed tomography revealed a mass in the right upper lung, and magnetic resonance imaging showed multiple brain metastases. Endobronchial ultrasound-guided transbronchial needle aspiration of the mass revealed sarcomatoid carcinoma with a low expression of programmed cell death ligand-1 (PD-L1), and the tumor proportion score was 10%, being classified as clinical stage IVB (cT3N0M1c [BRA]). Following stereotactic radiotherapy to the brain lesions, he was administered combination immunotherapy using nivolumab (360 mg/kg every 3 weeks) and ipilimumab (1 mg/kg every 6 weeks). We observed shrinkage of both lung and brain lesions, which was considered a partial response, and he showed only mild immunotherapy-induced toxicity. Conclusion. Immune checkpoint inhibitors may serve as an effective therapeutic option in patients with sarcomatoid carcinoma; combination therapy using these agents may provide an improved therapeutic benefit in such cases. (","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Lung Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2482/haigan.62.996","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

. ABSTRACT ━━ Background. Pulmonary pleomorphic carcinoma, a subtype of sarcomatoid carcinoma, is a rare lung malignancy. This cancer is usually resistant to chemo- and radiotherapy, and no standard treatment proto-cols are currently available. We herein report a case of sarcomatoid carcinoma in a patient who responded to combination therapy using nivolumab plus ipilimumab. Case. A 62-year-old man who was a current smoker was re-ferred to our hospital with right lower extremity paresis. Computed tomography revealed a mass in the right upper lung, and magnetic resonance imaging showed multiple brain metastases. Endobronchial ultrasound-guided transbronchial needle aspiration of the mass revealed sarcomatoid carcinoma with a low expression of programmed cell death ligand-1 (PD-L1), and the tumor proportion score was 10%, being classified as clinical stage IVB (cT3N0M1c [BRA]). Following stereotactic radiotherapy to the brain lesions, he was administered combination immunotherapy using nivolumab (360 mg/kg every 3 weeks) and ipilimumab (1 mg/kg every 6 weeks). We observed shrinkage of both lung and brain lesions, which was considered a partial response, and he showed only mild immunotherapy-induced toxicity. Conclusion. Immune checkpoint inhibitors may serve as an effective therapeutic option in patients with sarcomatoid carcinoma; combination therapy using these agents may provide an improved therapeutic benefit in such cases. (

查看原文本刊更多论文

纳武单抗加伊匹单抗联合免疫疗法成功治疗肉瘤样癌1例报告

。摘要━━背景。摘要肺多形性癌是一种罕见的肺恶性肿瘤，是肉瘤样癌的一个亚型。这种癌症通常对化疗和放疗具有耐药性，目前尚无标准的治疗方案。我们在此报告一例肉瘤样癌患者谁响应联合治疗使用纳武单抗和伊匹单抗。的情况。一位62岁男性吸烟者因右下肢麻痹转诊至我院。计算机断层扫描显示右上肺肿块，磁共振成像显示多发脑转移灶。经支气管超声引导下经支气管穿刺穿刺肿物，示肉瘤样癌，程序性细胞死亡配体-1 (PD-L1)低表达，肿瘤比例评分10%，临床分期IVB (cT3N0M1c [BRA])。脑病变立体定向放疗后，患者接受纳武单抗(每3周360 mg/kg)和伊匹单抗(每6周1 mg/kg)联合免疫治疗。我们观察到肺和脑病变的缩小，这被认为是部分反应，他只表现出轻微的免疫治疗引起的毒性。结论。免疫检查点抑制剂可作为肉瘤样癌患者的有效治疗选择;在这种情况下，使用这些药物的联合治疗可以提供更好的治疗效果。（

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Japanese Journal of Lung Cancer Medicine-Oncology

CiteScore

0.10

自引率

0.00%

发文量